TNGX
Tango TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
Successful positive clinical readouts and/or a strategic partnership/acquisition drive re-rating toward the high end of analyst dispersion; execution accelerates revenue pathway and reduces binary risk.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -1.9.
What can break
Analyst downgrades or consensus target cuts
Momentum
93
Value
41
Sentiment
3
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $15.50 · Bull $26.88 · Bear $10.10
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-03-07 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $44.33
Why
Momentum93 · Δ7d -1.9
Value41 · Δ7d +0.0
Sentiment3 · Δ7d +1.4
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
93
26% active weight
Current posture
7d trendFlat
Δ7d
-1.9
Δ21d
-6.2
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
3
34% active weight
Current posture
7d trendImproving
Δ7d
+1.4
Δ21d
+1.4
Why this grade
Composite grade D. Momentum 92.7 / Value 41.1 / Sentiment 3.0
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$4.48B
Beta
1.75
Shares Out
162.82M
P/E (TTM) · Derived
-31.5
P/S (TTM)
18.03
P/FCF (TTM) · Derived
-23.89
Rev YoY
-100.0%
EPS YoY
-12.3%
Gross Margin
+96.3%
Op Margin
-165.9%
Net Debt
-$310M
Current Ratio
27.38
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology